{"id":"https://openalex.org/W4392721804","doi":"https://doi.org/10.1158/2159-8290.c.6546029.v1","title":"Data from Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer","display_name":"Data from Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4392721804","doi":"https://doi.org/10.1158/2159-8290.c.6546029.v1"},"language":"en","primary_location":{"id":"doi:10.1158/2159-8290.c.6546029.v1","doi":"https://doi.org/10.1158/2159-8290.c.6546029.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2159-8290.c.6546029.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/2159-8290.c.6546029.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026737553","display_name":"Michel van Kruchten","orcid":"https://orcid.org/0000-0003-0897-2747","observed_orcids":["https://orcid.org/0000-0003-0897-2747"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michel van Kruchten","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061495577","display_name":"Elisabeth G.E. de Vries","orcid":"https://orcid.org/0000-0002-8949-7425","observed_orcids":["https://orcid.org/0000-0002-8949-7425"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elisabeth G. de Vries","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037547091","display_name":"Andor W.J.M. Glaudemans","orcid":"https://orcid.org/0000-0001-8081-0641","observed_orcids":["https://orcid.org/0000-0001-8081-0641"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andor W. Glaudemans","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054863547","display_name":"Meta C.J. van Lanschot","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meta C. van Lanschot","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066887433","display_name":"Martijn H. J. R. van Faassen","orcid":"https://orcid.org/0000-0002-9142-6263","observed_orcids":["https://orcid.org/0000-0002-9142-6263"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martijn van Faassen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019197669","display_name":"Ido P. Kema","orcid":"https://orcid.org/0000-0003-1166-6169","observed_orcids":["https://orcid.org/0000-0003-1166-6169"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ido P. Kema","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033532061","display_name":"Myles A Brown","orcid":"https://orcid.org/0000-0002-8213-1658","observed_orcids":["https://orcid.org/0000-0002-8213-1658"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Myles Brown","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108528208","display_name":"Carolien P. Schr\u00f6der","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carolien P. Schr\u00f6der","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002690933","display_name":"Erik F. J. de Vries","orcid":"https://orcid.org/0000-0002-6915-1590","observed_orcids":["https://orcid.org/0000-0002-6915-1590"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erik F. de Vries","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5013384569","display_name":"Geke A.P. Hospers","orcid":"https://orcid.org/0000-0002-3047-7892","observed_orcids":["https://orcid.org/0000-0002-3047-7892"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Geke A. Hospers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.7426999807357788,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.7426999807357788,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10756","display_name":"Estrogen and related hormone effects","score":0.11710000038146973,"subfield":{"id":"https://openalex.org/subfields/1310","display_name":"Endocrinology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.09769999980926514,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.9950000047683716},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9129999876022339},{"id":"https://openalex.org/keywords/antiestrogens","display_name":"antiestrogens","score":0.6610000133514404},{"id":"https://openalex.org/keywords/treatment-response-monitoring","display_name":"treatment response monitoring","score":0.7070000171661377},{"id":"https://openalex.org/keywords/early-disease-progression","display_name":"early disease progression","score":0.75},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.3619999885559082},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.5509999990463257}],"concepts":[{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.9783157110214233},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.7702243328094482},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6828553080558777},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6493918895721436},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.6070175170898438},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.594778835773468},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4908939003944397},{"id":"https://openalex.org/C2777164284","wikidata":"https://www.wikidata.org/wiki/Q277954","display_name":"Estrogen","level":2,"score":0.488521933555603},{"id":"https://openalex.org/C155512373","wikidata":"https://www.wikidata.org/wiki/Q287450","display_name":"Residual","level":2,"score":0.4820738434791565},{"id":"https://openalex.org/C3020687571","wikidata":"https://www.wikidata.org/wiki/Q3354346","display_name":"Estrogen therapy","level":3,"score":0.4412469267845154},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.42209166288375854},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.10304775834083557},{"id":"https://openalex.org/C11413529","wikidata":"https://www.wikidata.org/wiki/Q8366","display_name":"Algorithm","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2159-8290.c.6546029.v1","doi":"https://doi.org/10.1158/2159-8290.c.6546029.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2159-8290.c.6546029.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/2159-8290.c.6546029.v1","doi":"https://doi.org/10.1158/2159-8290.c.6546029.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/2159-8290.c.6546029.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2117634794","https://openalex.org/W2598428456","https://openalex.org/W2102542135","https://openalex.org/W2291433959","https://openalex.org/W2206889237","https://openalex.org/W2346572707","https://openalex.org/W2594830348","https://openalex.org/W3085105079","https://openalex.org/W3015737452","https://openalex.org/W4319062788"],"abstract_inverted_index":{"Abstract":[0],"It":[1],"is":[2,15,202],"unknown":[3],"whether":[4],"the":[5,141,163,205],"current":[6],"dose":[7,164],"of":[8,94,105,140,153,186],"fulvestrant,":[9],"an":[10],"estrogen":[11,155],"receptor":[12],"(ER)":[13],"antagonist,":[14],"sufficient":[16],"for":[17,166],"maximal":[18],"ER":[19,34,75,167,177],"downregulation":[20],"in":[21,74,82,112,137,179,184,204],"patients":[22,41,113],"with":[23,42,147,191],"metastatic":[24,44],"breast":[25,45],"cancer.":[26],"We":[27],"performed":[28],"a":[29,88],"feasibility":[30],"study":[31],"to":[32,66,126,169],"assess":[33],"availability":[35,76,178],"before":[36],"and":[37,61,87],"during":[38,114,181],"fulvestrant.":[39],"Sixteen":[40],"ER-positive":[43],"cancer":[46],"underwent":[47],"positron":[48],"emission":[49],"tomography/computed":[50],"tomography":[51],"(PET/CT)":[52],"at":[53,119,134],"baseline":[54],"(scan":[55,59,64],"1),":[56],"day":[57,62],"28":[58],"2),":[60],"84":[63],"3)":[65],"monitor":[67],"tumor":[68,84,130,154],"[18F]fluoroestradiol":[69],"(FES)":[70],"uptake.":[71],"Incomplete":[72],"reduction":[73],"was":[77,117,145,189],"predefined":[78],"as":[79],"<75%":[80],"decrease":[81],"median":[83,110],"FES":[85,131],"uptake":[86,91,132,156],"residual":[89,176],"standardized":[90],"value":[92],"(SUVmax)":[93],"\u22651.5.":[95],"In":[96,206],"total,":[97],"131":[98],"FES-positive":[99],"lesions":[100],"were":[101],"identified":[102],"(median":[103],"SUVmax":[104],"2.9;":[106],"range,":[107],"1.7\u20136.5).":[108],"The":[109],"change":[111],"fulvestrant":[115,182],"treatment":[116],"\u221285%":[118],"scan":[120,135],"2,":[121],"but":[122],"varied":[123],"widely":[124],"(\u221299%":[125],"+60%).":[127],"Fulvestrant":[128],"reduced":[129],"incompletely":[133],"2":[136],"6":[138],"(38%)":[139],"16":[142],"patients,":[143,187],"which":[144,188],"associated":[146,190],"early":[148,192],"progression.":[149,193],"Significance:":[150],"Serial":[151],"imaging":[152],"by":[157],"FES-PET":[158,173],"can":[159],"give":[160],"insight":[161],"into":[162],"needed":[165],"antagonists":[168],"completely":[170],"abolish":[171],"ER.":[172],"showed":[174],"significant":[175],"tumors":[180],"therapy":[183],"38%":[185],"Cancer":[194],"Discov;":[195],"5(1);":[196],"72\u201381.":[197],"\u00a92014":[198],"AACR.":[199],"This":[200,207],"article":[201],"highlighted":[203],"Issue":[208],"feature,":[209],"p.":[210],"1":[211]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2024-03-13T00:00:00"}